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 2 
The RNA-guided endonuclease Cas9 generates a double-strand break at DNA target sites 1 
complementary to the guide RNA, and has been harnessed for the development of a 2 
variety of new technologies, such as genome editing. Here, we report the crystal structures 3 
of Campylobacter jejuni Cas9 (CjCas9), one of the smallest Cas9 orthologs, in complex with 4 
an sgRNA and its target DNA. The structures provided insights into a minimal Cas9 5 
scaffold, and revealed the remarkable mechanistic diversity of the CRISPR-Cas9 systems. 6 
The CjCas9 guide RNA contains an unexpected triple-helix structure, which is distinct 7 
from known RNA triple helices, thereby expanding the natural repertoire of RNA triple 8 
helices. Furthermore, unlike the other Cas9 orthologs, CjCas9 contacts the nucleotide 9 
sequences in both the target and non-target DNA strands, and recognizes the 5′-10 
NNNVRYM-3′ as the protospacer adjacent motif. Collectively, these findings improve our 11 
mechanistic understanding of the CRISPR-Cas9 systems, and may facilitate Cas9 12 
engineering. 13 
  14 
 3 
Introduction 1 
Bacteria and Archaea utilize CRISPR-Cas (clustered regularly interspaced short palindromic 2 
repeats-CRISPR-associated) adaptive immune systems to defend themselves against foreign 3 
genetic elements, such as plasmids and phages (Marraffini, 2015; Barrangou and Doudna, 2016; 4 
Mohanraju et al., 2016; Wright et al., 2016). The CRISPR loci in the genome comprise a cas 5 
operon and a CRISPR array, consisting of short repetitive sequences (direct repeats) separated 6 
by non-repetitive sequences (spacers) derived from foreign genetic elements. The CRISPR array 7 
is transcribed and processed into CRISPR RNAs (crRNAs), which associate with single or 8 
multiple Cas proteins to form effector ribonucleoprotein complexes responsible for the 9 
destruction of invading nucleic acids (Makarova et al., 2015; Nishimasu and Nureki, 2016). In 10 
the type II CRISPR-Cas system, the Cas9 effector nuclease associates with dual guide RNAs 11 
(crRNA and trans-activating crRNA (tracrRNA)), and cleaves double-stranded (ds) DNA 12 
targets complementary to the crRNA guide (Garneau et al., 2010; Deltcheva et al., 2011; 13 
Gasiunas et al., 2012; Jinek et al., 2012). In addition to the crRNA-target DNA 14 
complementarity, Cas9-mediated target recognition requires a PAM (protospacer adjacent 15 
motif), a short nucleotide sequence adjacent to the target site (Deveau et al., 2008; Garneau et 16 
al., 2010). Importantly, a single-guide RNA (sgRNA), in which crRNA and tracrRNA are fused 17 
with an artificial tetraloop, can also direct Cas9 to the target cleavage (Jinek et al., 2012). Thus, 18 
the two component Cas9-sgRNA system has been harnessed for a variety of new technologies, 19 
including genome editing (Cong et al., 2013; Jinek et al., 2013; Mali et al., 2013). 20 
 21 
Structural studies of Streptococcus pyogenes Cas9 (SpCas9) have provided mechanistic details 22 
of the RNA-guided DNA cleavage by the Cas9 enzyme. The crystal structure of SpCas9 in its 23 
apo form revealed a bilobed architecture comprising an α-helical recognition (REC) lobe and a 24 
nuclease (NUC) lobe (Jinek et al., 2014). The crystal structure of SpCas9 bound to the sgRNA 25 
and its single-stranded DNA target clarified the recognition mechanism of the sgRNA and the 26 
target DNA (Nishimasu et al., 2014). Subsequently, the crystal structure of SpCas9 bound to the 27 
sgRNA and a PAM-containing DNA revealed the recognition mechanism of the 5′-NGG-3′ 28 
PAM by SpCas9 (Anders et al., 2014). Moreover, the crystal structures of SpCas9 bound to the 29 
sgRNA (Jiang et al., 2015) and SpCas9 bound to an R-loop (Jiang et al., 2016) demonstrated the 30 
structural rearrangements in the Cas9 protein accompanying the guide RNA binding and R-loop 31 
formation, respectively. 32 
 33 
 4 
The Cas9 orthologs from different microbes have highly divergent sequences, function with 1 
their cognate crRNA:tracrRNA guides, and recognize a variety of PAM sequences (Chylinski et 2 
al., 2013; Fonfara et al., 2014; Hsu et al., 2014; Karvelis et al., 2015; Ran et al., 2015). SpCas9 3 
(1,368 aa) recognizes 5′-NGG-3′ as the PAM (Mojica et al., 2009), whereas Staphylococcus 4 
aureus Cas9 (SaCas9, 1,053 aa) and Francisella novicida Cas9 (FnCas9, 1,629 aa) recognize 5′-5 
NNGRRT-3′ and 5′-NGG-3′ as the PAMs, respectively (Ran et al., 2015; Hirano et al., 2016). A 6 
structural comparison of SpCas9 (Anders et al., 2014; Nishimasu et al., 2014) with SaCas9 7 
(Nishimasu et al., 2015) and FnCas9 (Hirano et al., 2016) revealed that, while they share the 8 
conserved RuvC and HNH nuclease domains, their REC and Wedge (WED) domains are 9 
structurally divergent, and recognize distinct structural features in their cognate RNA guides. In 10 
addition, their PAM-interacting (PI) domains share a conserved core fold, but recognize distinct 11 
PAM sequences, using a specific set of amino-acid residues. 12 
 13 
Campylobacter jejuni Cas9 (CjCas9) has several unique features (Fonfara et al., 2014). First, 14 
CjCas9 consists of 984 residues, and is one of the smallest Cas9 orthologs. Second, the 15 
nucleotide sequences of the crRNA:tracrRNA guides for CjCas9 and the other Cas9 orthologs 16 
differ substantially. Third, CjCas9 recognizes the 5′-NNNNACA-3′ PAM, whereas most Cas9 17 
orthologs, as exemplified by SpCas9 (5′-NGG-3′) (Gasiunas et al., 2012; Jinek et al., 2012), 18 
recognize G-rich PAMs. However, the functional mechanism of CjCas9 remains elusive, due to 19 
the lack of structural information. 20 
 21 
Here, we performed functional and structural characterizations of CjCas9. In vitro cleavage 22 
experiments revealed that CjCas9 recognizes the 5′-NNNVRYM-3′ PAM, which is more 23 
promiscuous than the previously reported PAMs. The crystal structure of the CjCas9-sgRNA-24 
target DNA complex highlighted the remarkable mechanistic diversity of the CRISPR-Cas9 25 
systems. Unlike the tracrRNAs for the other Cas9 orthologs, the CjCas9 tracrRNA has an 26 
unanticipated triple-helix structure, which is distinct from known RNA triple helices. 27 
Furthermore, CjCas9 recognizes the PAM nucleotides on both the target and non-target DNA 28 
strands, whereas the other Cas9 orthologs recognize the PAM nucleotides on the non-target 29 
DNA strand. 30 
 31 
Results and Discussion 32 
 33 
CjCas9 PAM specificity 34 
 5 
Although a previous study reported that CjCas9 recognizes the 5′-NNNNACA-3′ PAM (Fonfara 1 
et al., 2014), the CjCas9 PAM has not been fully characterized. To determine the CjCas9 PAM, 2 
we performed the PAM discovery assay, using purified CjCas9, an sgRNA and a library of 3 
plasmid DNA targets with a degenerate 7-bp PAM sequence, as described previously (Ran et 4 
al., 2015; Zetsche et al., 2015). The result revealed that CjCas9 recognizes the 5′-NNNVRYM-5 
3′ PAM (V is A/G/C; R is A/G; Y is T/C; M is A/C) (Figures 1A and S1), which is more 6 
promiscuous than the previously reported 5′-NNNNACA-3′ PAM (Fonfara et al., 2014). Using 7 
purified CjCas9 and an sgRNA, we further examined the cleavage of 13 plasmid DNA targets 8 
with either 5′-AGANACC-3′, 5′-AGAANCA-3′, 5′-AGAAANA-3′ or 5′-AGAACN-3′ as the 9 
PAMs. The results confirmed that CjCas9 efficiently recognizes the 5′-NNNVRYM-3′ PAM, 10 
with the preference for T and C at positions 6 and 7, respectively (Figures 1B and 1C). 11 
 12 
Crystal structure of the CjCas9-sgRNA-target DNA complex 13 
To clarify the RNA-guided DNA recognition mechanism of CjCas9, we attempted to determine 14 
the crystal structure of CjCas9 in complex with an sgRNA and its target DNA. However, we 15 
failed to obtain diffraction-quality crystals. Previous studies revealed that the HNH nuclease 16 
domain of SpCas9 is mobile and dispensable for RNA-guided DNA recognition (Nishimasu et 17 
al., 2014; Jiang et al., 2015; Sternberg et al., 2015), suggesting that the flexibility of the HNH 18 
domain may hamper the crystallization. We thus prepared the CjCas9-∆HNH variant lacking the 19 
HNH domain (residues 481–640), in which Leu480 (RuvC-II) and Tyr641 (RuvC-III) are 20 
connected by a GGGSGG linker (Figure 2A). After extensive crystallization screening, we 21 
determined the crystal structure of CjCas9-∆HNH in complex with a 93-nt sgRNA, a 28-nt 22 
target DNA strand, and an 8-nt non-target DNA strand containing the 5′-AGAAACC-3′ PAM, 23 
at 2.4 Å resolution (Figures 2A–2C and Table 1). 24 
 25 
The crystal structure revealed that CjCas9 adopts a bilobed architecture comprising the α-helical 26 
REC lobe and a NUC lobe, as in the other Cas9 orthologs (Anders et al., 2014; Nishimasu et al., 27 
2014; Nishimasu et al., 2015) (Figure 2C), indicating that the truncation of the HNH domain 28 
does not substantially affect the overall structure. The REC lobe can be divided into the REC1 29 
(residues 77–234) and REC2 (residues 235–426) domains. The NUC lobe comprises the RuvC 30 
(residues 1–44, 427–480 and 641–777), WED (residues 792–827), and PI domains (residues 31 
828–984) (the HNH domain was truncated for crystallization). The REC and NUC lobes are 32 
connected by an arginine-rich “bridge” helix (residues 45–76), while the WED and RuvC 33 
domains are connected by a “phosphate lock” loop (residues 778–791), as in other Cas9 34 
 6 
orthologs (Anders et al., 2014; Nishimasu et al., 2014; Nishimasu et al., 2015; Hirano et al., 1 
2016). The three residues (GGS) in the GGGSGG linker between the RuvC-II and RuvC-III 2 
motifs are disordered in the present structure. 3 
 4 
The sgRNA comprises the guide segment (G1–C20), the repeat region (G21–U32), the tetraloop 5 
(G33–A36), the antirepeat region (A37–U48), and the tracrRNA scaffold (A49–C93) (Figure 6 
2B). The guide segment (G1–C20) and the target DNA strand (dG1–dC20) form an RNA-DNA 7 
heteroduplex (Figures 2B and 2C). The repeat and antirepeat regions form the A-form-like 8 
duplex (referred to as the repeat-antirepeat duplex), which consists of a wobble base pair 9 
(G21•U48) and eleven Watson-Crick base pairs (U22-A47–U32-A37) (Figures 2B and 2C). The 10 
RNA-DNA heteroduplex is bound within the central channel between the REC and NUC lobes, 11 
while the repeat-antirepeat duplex is sandwiched between the REC1 and WED domains (Figure 12 
2C). These duplexes are primarily recognized by the protein in a non-sequence-specific manner 13 
(Figure S2). The target DNA strand (dC(−8)–dT(−1)) and the non-target DNA strand (dA1*–14 
dG8*) form a PAM-containing duplex, which is recognized by the WED and PI domains 15 
(Figures 2B and 2C). 16 
 17 
A recent study showed that the deletion of the HNH domain in SpCas9 impairs the non-target 18 
strand cleavage by the RuvC domain, thereby suggesting that the HNH domain is required for 19 
the activation of the RuvC domain (Sternberg et al., 2015). We thus examined the effect of the 20 
deletion of the HNH domain on the CjCas9 activity, using in vitro cleavage assays. Our results 21 
revealed that, like the D8A RuvC-inactive nickase and the H559A HNH-inactive nickase, the 22 
CjCas9-ΔHNH variant functions as a nickase (Figure 2D). Importantly, the CjCas9-ΔHNH 23 
variant exhibited lower cleavage activity, as compared with the H559A nickase, indicating that 24 
the deletion, but not the inactivating point mutation, of the HNH domain reduces the non-target 25 
strand cleavage by the RuvC domain. These observations suggested the allosteric 26 
communication between the RuvC and HNH nuclease domains in CjCas9, as observed in 27 
SpCas9 (Sternberg et al., 2015). 28 
 29 
TracrRNA architecture 30 
Notably, the present structure revealed that the CjCas9 tracrRNA scaffold contains a triple-helix 31 
structure within a pseudoknot comprising three stem regions, which was not predicted from its 32 
primary sequence (Figures 3A–3C). Stem 1 consists of four canonical base pairs (A51-U67–33 
G54-C64) and a non-canonical A50•G68 base pair, while stem 2 consists of four canonical base 34 
 7 
pairs (G58-C93–G61-C90) and a non-canonical G62•A89 base pair (Figures 3B and 3C). Stem 1 
3 consists of four canonical base pairs (G70-C84–G74-C81) (Figures 3B and 3C). Nucleotides 2 
56/57 and 86/87 form base pairs with stem 2 and stem 1, respectively, thereby contributing to 3 
the triple-helix formation. U65 in stem 1 and A89 in stem 2 base pair with A86 and U56, 4 
forming an A53-U65•A86 minor-groove triple and a G62-A89•U56 major-groove triple, 5 
respectively (Figures 3D and 3E). U57 base pairs with C59 and C90, forming a G92-6 
C59•U57•C90-G62 base quintuple (Figure 3F). A87 and A88 base pair with G54 and U55/C64, 7 
respectively, forming a U55•A88•C64-G54•A87 base quintuple (Figure 3G). 8 
 9 
The tracrRNA scaffold is extensively recognized by CjCas9 (Figures 4A and S2). In particular, 10 
A63, A76 and U80 are flipped out, and recognized by the protein in base-specific manners. The 11 
nucleobase and ribose moieties of A63 form stacking interactions with the side chains of His70 12 
and His67, respectively, while the N1 of A63 hydrogen bonds with the side chain of Asn74 13 
(Figure 4B). A76 and U80 are accommodated within specific pockets in the PI domain (Figure 14 
4A). The nucleobase of A76 is sandwiched between the side chains of Ile964 and Arg977, while 15 
the N6 and N7 of A76 hydrogen bond with the main-chain carbonyl and amide groups of 16 
Glu975, respectively (Figure 4C). The nucleobase of U80 is sandwiched between the side 17 
chains of Phe854 and Glu980, while the N3 and O4 of U80 hydrogen bond with the main-chain 18 
carbonyl group of Asp981 and the side chain of Arg832, respectively (Figure 4C). Indeed, the 19 
single mutations (A63U, A76U or U80A) reduced CjCas9-mediated DNA cleavage (Figure 20 
4D), confirming the functional importance of the three flipped-out nucleotides. Moreover, a 4-nt 21 
substitution (nucleotides 90–93) or an 8-nt deletion (nucleotides 86–93) in the tracrRNA 3′ tail 22 
abolished the CjCas9-mediated DNA cleavage (Figure 4D), indicating that the triple-helix 23 
structure of the tracrRNA is critical for the activity. In addition, the SpCas9 sgRNA did not 24 
support the CjCas9-mediated DNA cleavage (Figure 4D). Together, these results demonstrated 25 
that CjCas9 specifically recognizes its cognate RNA guide. 26 
 27 
5′-NNNVRYM-3′ PAM recognition 28 
In the present structure, the 5′-AGAAACC-3′ PAM-containing DNA duplex is bound to the 29 
cleft between the WED and PI domains (Figure 5A). The nucleobases of dA1*–dA3* do not 30 
directly contact the protein (Figures 5B and 5C), consistent with the lack of specificity for 31 
positions 1–3 in the 5′-NNNVRYM-3′ PAM. The N7 of dA4* in the non-target strand forms a 32 
water-mediated hydrogen bond with the side-chain hydroxyl group of Thr913 (Figures 5B and 33 
5C). Modeling suggested that a steric clash could occur between the methyl group of dT4* and 34 
 8 
the side chain of Thr913 (Figures S3A and S3B), consistent with the preference of CjCas9 for 1 
the fourth V (A/G/C). The N7 of dA5* in the non-target strand forms a hydrogen bond with the 2 
side-chain hydroxyl group of Ser915 (Figures 5B and 5C). Since N7 is common among the 3 
purine nucleotides, the interaction can explain the requirement for the fifth R (A/G). Notably, 4 
the nucleobase of dC6* in the non-target strand is not recognized by the protein (Figures 5B and 5 
5C). Instead, the N7 of dG(−6) in the target strand forms a hydrogen bond with the side-chain 6 
hydroxyl group of Ser951 (Figures 5B and 5C). These structural findings revealed that CjCas9 7 
does not recognize the Y (T/C) nucleotides at position 6 in the non-target strand as the PAM, 8 
but detects their complementary R (A/G) nucleotides in the target strand. Similarly, the 9 
nucleobase of dC7* in the non-target strand is not recognized by the protein, whereas the O6 10 
and N7 of dG(−7) in the target strand form bidentate hydrogen bonds with the side chain of 11 
Arg866 (Figures 5B and 5C). In addition to the 5′-AGAAACC-3′ PAM complex, we 12 
determined the crystal structure of CjCas9-∆HNH in complex with the sgRNA and the DNA 13 
target containing the 5′-AGAAACA-3′ PAM (Table 1). In the 5′-AGAAACA-3′ PAM complex, 14 
the dT(−7):dA7* pair in the PAM duplex undergo a slight displacement toward the PI domain, 15 
as compared with the dG(−7):dC7* pair in the 5′-AGAAACC-3′ PAM complex (Figure S3C). 16 
This displacement in the PAM duplex allows Arg866 to form a hydrogen bond with the O4 of 17 
dT(−7) in the target strand (Figure S3D). These observations revealed that CjCas9 does not 18 
recognize the M (A/C) nucleotides at position 7 in the non-target strand as the PAM, but detects 19 
their complementary K (T/G) nucleotides in the target strand. The preference of CjCas9 for C 20 
over A at position 7 can be explained by the bidentate hydrogen-bonding interaction between 21 
dG(−7) and Arg866, in contrast to the single hydrogen-bonding interaction between dT(−7) and 22 
Arg866. The single mutations of Arg866, Thr913, Ser915, and Ser951 reduced or abolished the 23 
in vitro cleavage activity (Figure 5D), confirming their functional importance. Together, our 24 
structural and functional data revealed that CjCas9 forms sequence-specific contacts with both 25 
the target and non-target DNA strands, to achieve the recognition of the 5′-NNNVRYM-3′ 26 
PAM. 27 
 28 
Structural comparison between the Cas9 orthologs 29 
A structural comparison of CjCas9 with the other Cas9 orthologs highlighted the structural 30 
similarities and differences between the CRISPR-Cas9 systems, and provided insights into a 31 
minimal Cas9 scaffold (Figure 6). Unlike SpCas9 (Anders et al., 2014; Nishimasu et al., 2014), 32 
the smaller SaCas9 (Nishimasu et al., 2015) and CjCas9 lack the insertion subdomains within 33 
the REC1 and PI domains (Figures 6A–6C). Furthermore, the WED domain of CjCas9 (36 34 
 9 
amino acids) is smaller than that of SaCas9 (122 amino acids) (Figures 6A and 6C). These 1 
structural differences contribute to the miniaturization of CjCas9. The REC and WED domains 2 
of FnCas9, one of the largest Cas9 orthologs, adopt protein folds distinct from those of CjCas9, 3 
SpCas9 and SaCas9 (Hirano et al., 2016) (Figure 6D), reinforcing the notion that FnCas9 is 4 
distantly related to the other Cas9 orthologs. 5 
 6 
Despite the structural differences in these individual domains, CjCas9 adopts the conserved 7 
bilobed architecture, and accommodates the RNA-DNA heteroduplex in similar manners to 8 
those of the other Cas9 orthologs (Figures 6A–6D). The sugar-phosphate backbone of the 9 
sgRNA “seed” region (C13–C20) is extensively recognized by conserved arginine residues in 10 
the bridge helix (Figure S4A). In addition, the backbone phosphate group between dG1 and 11 
dT(−1) in the target DNA strand (referred to as the +1 phosphate (Anders et al., 2014)) interacts 12 
with the main-chain amide groups of Glu790 and Thr791 and the side-chain hydroxyl group of 13 
Thr791 in the phosphate lock loop, thereby facilitating target DNA unwinding (Figure S4B). 14 
Indeed, the T791A mutation abolished the in vitro DNA cleavage activity (Figure S4C), 15 
confirming the functional importance of the interaction between the +1 phosphate and Thr791. 16 
These observations confirmed that the RNA-guided DNA targeting mechanism is highly 17 
conserved among the CRISPR-Cas9 systems. 18 
 19 
The present structure also illuminated the structural diversity of the crRNA:tracrRNA guides in 20 
the CRISPR-Cas9 systems (Figures 6E–6H). The repeat-antirepeat duplexes for SpCas9, 21 
SaCas9 and FnCas9 contain several unpaired nucleotides, and thus adopt distorted, distinct 22 
structures (Nishimasu et al., 2014; Nishimasu et al., 2015; Hirano et al., 2016) (Figures 6F–6H). 23 
In contrast, the CjCas9 repeat-antirepeat duplex adopts an A-form-like conformation (Figure 24 
6E). According to these structural differences, the repeat-antirepeat duplexes are recognized by 25 
the structurally divergent REC1 and WED domains in species-specific manners (Figure S5). 26 
The CjCas9-REC1 adopts a conserved core fold, but has two unique loops (loops 1 and 2) that 27 
interact with the repeat-antirepeat duplex. The repeat-antirepeat duplex is further recognized by 28 
the WED domain, which is structurally distinct from those of the other Cas9 orthologs. 29 
Furthermore, the present structure revealed the notable architectural differences in the tracrRNA 30 
scaffolds. The SpCas9 and SaCas9 tracrRNA scaffolds contain three and two stem loops, 31 
respectively, and the first and second stem loops are connected by a single-stranded linker 32 
(although stem loop 2 of SaCas9 was truncated for crystallization) (Nishimasu et al., 2014; 33 
Nishimasu et al., 2015) (Figures 6F and 6G). The FnCas9 tracrRNA scaffold contains two stem 34 
 10 
loops, which are connected by a U-shaped linker (Hirano et al., 2016) (Figure 6H). In stark 1 
contrast, the CjCas9 tracrRNA scaffold contains a more complicated triple-helix structure, as 2 
described above (Figure 6E). 3 
 4 
Mechanistic diversity in PAM recognition 5 
Despite their limited sequence similarity, the PI domains of the Cas9 orthologs share a similar 6 
core fold comprising two distorted β-sheets (β1–β3 and β4–β9) (Figures 7A–7D). In SpCas9, 7 
SaCas9 and FnCas9, distinct sets of amino-acid residues in the β5–β7 region form sequence-8 
specific contacts with the PAM nucleotides on the non-target DNA strand (Anders et al., 2014; 9 
Nishimasu et al., 2015; Hirano et al., 2016). In SpCas9, Arg1333 and Arg1335 form bidentate 10 
hydrogen bonds with the second and third Gs in the 5′-NGG-3′ PAM, respectively (Anders et 11 
al., 2014) (Figure 7B). In SaCas9, Arg1015 forms a bidentate hydrogen bond with the third G in 12 
the 5′-NNGRRT-3′ PAM, while Asn985, Asn986 and Arg991 form a hydrogen-bonding 13 
network with the RRT nucleotides (Nishimasu et al., 2015) (Figure 7C). In FnCas9, Arg1585 14 
and Arg1556 form bidentate hydrogen bonds with the second and third Gs in the 5′-NGG-3′ 15 
PAM, respectively (Hirano et al., 2016) (Figure 7D). In contrast to these Cas9 orthologs, 16 
CjCas9 forms sequence-specific contacts with the PAM nucleotides on the non-target strand and 17 
the PAM-complementary nucleotides on the target strand (Figure 7A), illuminating the 18 
mechanistic diversity of Cas9-mediated PAM recognition. Intriguingly, a recent study showed 19 
that the mutations of the PAM-complementary nucleotides on the target strand abolished the 20 
cleavage activity of Neisseria meningitidis Cas9 (Zhang et al., 2015), suggesting that other Cas9 21 
orthologs, such as N. meningitidis Cas9, also form sequence-specific interactions with both the 22 
target and non-target DNA strands in the PAM duplex, as observed in CjCas9. Further studies 23 
will be required to fully elucidate the mechanistic diversity in the PAM recognition by Cas9 24 
orthologs. 25 
 26 
Comparison of the cleavage activities of CjCas9 and SpCas9  27 
A recent study showed that the type II-C Cas9 from Corynebacterium diphtheriae (CdCas9), 28 
which consists of 1084 residues and shares 21% sequence identity with CjCas9, has limited 29 
unwinding and cleavage activities toward dsDNA targets, as compared with SpCas9 (Ma et al., 30 
2015). This result suggested that the inefficiency of most of the type II-C Cas9 orthologs for 31 
genome editing results from their limited dsDNA cleavage activities (Ma et al., 2015). To 32 
examine the differences in the catalytic features of CjCas9 and SpCas9, we compared their in 33 
vitro dsDNA cleavage activities. Our data revealed that, like CdCas9, CjCas9 cleaves the target 34 
 11 
dsDNA less efficiently, as compared with SpCas9 (Figure S6). These results support the notion 1 
that the type II-C Cas9 enzymes, such as CdCas9 and CjCas9, have not been harnessed for 2 
genome editing at least partly because of their relatively poor activities. Thus, it is possible that 3 
an engineered CjCas9 variant with improved dsDNA cleavage activity could be used for 4 
eukaryotic genome editing. Although CjCas9 and CdCas9 commonly exhibit relatively weak 5 
dsDNA cleavage activities, they may have distinct specificities for their cognate RNA guides. In 6 
contrast to CjCas9, which is specific to its cognate sgRNA, CdCas9 promiscuously recognizes 7 
the SpCas9 sgRNA as well as its cognate sgRNA (Ma et al., 2015). Further structural studies 8 
will provide insights into the mechanistic diversity among the type II-C CRISPR-Cas9 systems. 9 
 10 
Structural comparison of the CjCas9 tracrRNA and other known RNA triplexes 11 
A structural comparison of the CjCas9 tracrRNA with previously characterized RNA triplexes, 12 
such as the telomerase RNA subunit TER (Theimer et al., 2005), the SAM-II riboswitch 13 
(Gilbert et al., 2008), and the long noncoding RNA MALAT1 (Brown et al., 2014), revealed 14 
notable differences between the CjCas9 tracrRNA and the other RNA triplexes (Figure S7). 15 
Notably, the CjCas9 tracrRNA lacks a canonical U•A-U triple, whereas the other three RNA 16 
triplexes contain successive U•A-U triples (Figure S7). TER and SAM-II have three and seven 17 
U•A-U triples in their core regions, respectively. In particular, MALAT1 forms a bipartite triple 18 
helix containing stacks of five and four U•A-U triples. Moreover, in the CjCas9 tracrRNA, the 19 
L1 region between the S1 and S2 regions consists of three nucleotides and is shorter than those 20 
of the other three RNA triplexes (Figure S7). Thus, the CjCas9 tracrRNA adopts a distorted 21 
structure, which is stabilized by the two base triples and the two base quintuples. Taken 22 
together, the CjCas9-sgRNA-DNA structure revealed the previously unrecognized biological 23 
role of an RNA triple helix. 24 
 25 
Conclusions 26 
The present structure of the CjCas9-sgRNA-target DNA complex unveiled the remarkable 27 
diversity among the CRISPR-Cas9 systems. First, unlike the other tracrRNAs, the CjCas9 28 
tracrRNA contains a triple-helix architecture, which is distinct from other known RNA 29 
triplexes, thereby expanding the natural repertoire of RNA triplexes. Second, unlike other Cas9 30 
orthologs, CjCas9 reads the nucleotide sequences in both the target and non-target DNA strands 31 
as the PAM. Although CjCas9 has not been harnessed for genome editing applications, our 32 
structural findings may provide clues for Cas9 engineering, such as miniaturization of Cas9 and 33 
alteration of its PAM specificities. 34 
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STAR METHODS 1 
 2 
CONTACT FOR REAGENT AND RESOURCE SHARING 3 
Requests for further information and reagents should be directed to the Lead Contact, Osamu 4 
Nureki (nureki@bs.s.u-tokyo.ac.jp). 5 
 6 
EXPERIMENTAL MODEL AND SUBJECT DETAILS 7 
The plasmid DNAs were amplified in Escherichia coli Mach (Thermo Fisher Scientific), 8 
cultured in LB medium (Nacalai Tesque) at 37°C overnight. The recombinant proteins were 9 
overexpressed in E. coli Rosetta 2 (DE3) (Novagen). The E. coli cells were cultured at 37°C in 10 
LB medium (containing 20 mg/l kanamycin) until the OD600 reached 0.8, and then protein 11 
expression was induced by the addition of 0.5 mM isopropyl-b-D-thiogalactopyranoside 12 
(Nacalai Tesque) and an incubation at 20°C for 20 h. 13 
 14 
Sample preparation 15 
The gene encoding full-length CjCas9 (residues 1–984) was codon optimized, synthesized 16 
(Genscript), and cloned between the NdeI and XhoI sites of the modified pE-SUMO vector 17 
(LifeSensors). For crystallization, we prepared the CjCas9-ΔHNH variant lacking the HNH 18 
domain (residues 481–640), in which Leu480 (RuvC-II) and Tyr641 (RuvC-III) are connected 19 
by a GGGSGG linker. The CjCas9-ΔHNH variant was created by a PCR-based method, using 20 
the vector encoding the full-length CjCas9 as the template. The CjCas9-ΔHNH protein was 21 
expressed at 20°C in E. coli Rosetta 2 (DE3), and was purified by chromatography on Ni-NTA 22 
Superflow resin (QIAGEN). The eluted protein was purified by chromatography on a HiTrap 23 
Heparin HP column (GE Healthcare), and was then dialyzed overnight at 20°C with TEV 24 
protease, to remove the N-terminal His6-SUMO-tag. The CjCas9-ΔHNH protein was further 25 
purified by chromatography on NiNTA and HiLoad 16/600 Superdex 200 (GE Healthcare) 26 
columns. The selenomethionine (SeMet)-substituted CjCas9-ΔHNH was expressed in E. coli 27 
B834 (DE3) (Novagen), and was purified using a similar protocol to that for the native protein. 28 
The sgRNA was transcribed in vitro with T7 RNA polymerase, using a PCR-amplified dsDNA 29 
template. The transcribed RNA was purified by 8% denaturing (7 M urea) polyacrylamide gel 30 
electrophoresis. The target and non-target DNA strands were purchased from Sigma-Aldrich. 31 
The purified CjCas9-ΔHNH protein was mixed with the sgRNA, the target DNA strand, and the 32 
non-target DNA strand (containing either the 5′-AGAAACA-3′ PAM or the 5′-AGAAACC-3′ 33 
PAM) (molar ratio, 1:1.5:2.3:3.4), and then the CjCas9-sgRNA-DNA complex was purified by 34 
 17 
gel filtration chromatography on a Superdex 200 Increase column (GE Healthcare). For in vitro 1 
cleavage assays, the wild type and mutants of full-length CjCas9 were expressed and purified, 2 
using a protocol similar to that for CjCas9-ΔHNH. 3 
 4 
Crystallography 5 
The purified CjCas9-sgRNA-DNA complex (containing either the 5′-AGAAACA-3′ PAM or 6 
the 5′-AGAAACC-3′ PAM) was grown at 20°C, using the hanging-drop vapor diffusion 7 
method. Crystals were obtained by mixing 1 µl of complex solution (A260 nm = 15) and 1 µl of 8 
reservoir solution (12.0–14.5% PEG 2,000, 0.4 M ammonium acetate). The SeMet-labeled 9 
complex (containing the 5′-AGAAACA-3′ PAM) was crystallized under similar conditions. X-10 
ray diffraction data were collected at 100 K on beamlines BL41XU at SPring-8 and PXI at the 11 
Swiss Light Source. The crystals were cryoprotected in reservoir solution supplemented with 12 
25% ethylene glycol. X-ray diffraction data were processed using DIALS (Waterman et al., 13 
2013) and AIMLESS (Evans and Murshudov, 2013). The structure was determined by the Se-14 
SAD method, using PHENIX AutoSol (Adams et al., 2010). The model was automatically built 15 
using Buccaneer (Cowtan, 2006), followed by manual model building using COOT (Emsley 16 
and Cowtan, 2004) and structural refinement using PHENIX (Adams et al., 2010). The final 17 
models of the 5′-AGAAACA-3′ PAM complex (2.3 Å resolution) and the 5′-AGAAACC-3′ 18 
PAM complex (2.4 Å resolution) were refined using native data sets. Data collection statistics 19 
are summarized in Table 1. Structural figures were prepared using CueMol 20 
(http://www.cuemol.org). 21 
 22 
PAM discovery assay 23 
To generate plasmid libraries containing randomized PAM sequences, synthesized ssDNA 24 
oligonucleotides (Integrated DNA Technologies), consisting of seven randomized nucleotides 3′ 25 
of a 20-nt target sequence, were used to generate dsDNAs through annealing to a short primer 26 
and extension by the large Klenow fragment (New England Biolabs). The dsDNAs were 27 
subsequently cloned into linearized pUC19 with Gibson cloning (New England Biolabs). To 28 
propagate and purify the cloned plasmids, the products were used to transform >107 competent 29 
Stbl3 E. coli cells (Invitrogen), which were pooled and harvested with a Maxi-prep kit 30 
(QIAGEN) after overnight growth. The randomized PAM plasmid library was cleaved in vitro, 31 
using purified CjCas9 with sgRNAs targeting the PAM library, and the cleavage products were 32 
separated on 2% agarose E-gels (Life Technologies). The band corresponding to the un-cleaved 33 
target plasmid was isolated with a Zymoclean Gel DNA Recovery Kit (Zymo Research), and 34 
the region surrounding the randomized PAM region was PCR-amplified and sequenced using a 35 
 18 
MiSeq sequencer (Illumina) with 150 single-end cycles. To analyze the resulting sequence data, 1 
the seven nucleotide PAM region was extracted, the individual PAMs were counted, and the 2 
PAM counts were normalized to the total reads for each sample. For a given PAM sequence, the 3 
enrichment was measured as the log2 ratio as compared to a no-protein control, with a 0.01 4 
pseudocount adjustment. PAMs above an enrichment threshold set to 3.5 were compiled and 5 
used to generate sequence logos (Crooks et al., 2004). For the PAM wheel generation, 6 
abundances were used to generate wheels with Krona (Ondov et al., 2011), as described in the 7 
previous report (Leenay et al., 2016). The ratios of PAM abundances as compared to a no-8 
protein control, with a 0.01 pseudocount adjustment, were used directly as input for Krona. 9 
 10 
In vitro cleavage assay 11 
In vitro plasmid DNA cleavage experiments were performed essentially as described previously 12 
(Nishimasu et al., 2015). The EcoRI-linearized pUC119 plasmid (100 ng, 4.7 nM), containing 13 
the 20-nt target sequence and the PAMs, was incubated at 37°C for 5 min with the CjCas9-14 
sgRNA complex (100 nM, molar ratio, 1:1.5), in 10 µl of reaction buffer containing 20 mM 15 
HEPES, pH 7.5, 100 mM KCl, 2 mM MgCl2, 1 mM DTT and 5% glycerol. Reaction products 16 
were resolved on a 1% agarose gel, stained with ethidium bromide, and then visualized using a 17 
Typhoon FLA 9500 imager (GE Healthcare). 18 
 19 
METHOD DETAILS QUANTIFICATION AND STATISTICAL ANALYSES 20 
In vitro cleavage experiments were performed at least three times, and representative results 21 
were shown. 22 
 23 
DATA AND SOFTWARE AVAILABILITY 24 
The atomic coordinates of the CjCas9-sgRNA-DNA complexes have been deposited in the 25 
Protein Data Bank, with the accession numbers PDB: 5X2G (5′-AGAAACC-3′ PAM) and 26 
5X2H (5′-AGAAACA-3′ PAM). Data of in vitro cleavage experiments have been deposited in 27 
the Mendeley Data repository (http://dx.doi.org/doi:10.17632/6v2dwwcgs3.1). The CueMol 28 
program is available at http://www.cuemol.org. 29 
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Figure Legends 1 
 2 
Figure 1 CjCas9 PAM specificity 3 
(A) Motif obtained from the in vitro PAM discovery assay. 4 
(B and C) In vitro cleavage assays for DNA targets with different PAMs. The linearized 5 
plasmid targets with either the 5′-AGAANCA-3′, 5′-AGAAANA-3′ or 5′-AGAACN-3′ PAM 6 
(B), or the 5′-AGANACC-3′ PAM (C) were incubated with CjCas9-sgRNA, and then analyzed 7 
by agarose gel electrophoresis. 8 
See also Figure S1. 9 
 10 
Figure 2 Overall structure 11 
(A) Domain structure of CjCas9. The HNH nuclease domain was truncated for crystallization. 12 
BH, bridge helix; PLL, phosphate lock loop. 13 
(B) Schematics of the sgRNA and the target DNA. TS, target strand; NTS, non-target strand. 14 
(C) Overall structure of CjCas9-∆HNH in complex with an sgRNA and its target DNA. The 15 
predicted location of the HNH domain is indicated by the pink circle. 16 
(D) In vitro cleavage activity of CjCas9-∆HNH. The circular and linearized plasmid targets with 17 
the 5′-AGAAACC-3′ PAM were incubated with wild-type CjCas9 or the three CjCas9 variants 18 
(D8A, H559A and ∆HNH), and then were analyzed by agarose gel electrophoresis. The D8A 19 
and H559A variants of CjCas9 correspond to the D10A and H840A nickases of SpCas9, 20 
respectively. 21 
See also Figure S2 and Table 1. 22 
 23 
Figure 3 TracrRNA scaffold 24 
(A) 2mFO – DFC electron density map for the tracrRNA scaffold (contoured at 2σ). 25 
(B) Schematics of the tracrRNA scaffold. Non-Watson-Crick base pairs are indicated with 26 
Leontis-Westhof notations (Leontis et al., 2002). The base triples and quintuples are highlighted 27 
in gray and orange backgrounds, respectively. 28 
(C) Structure of the CjCas9 tracrRNA scaffold (stereo view). The 3′ nucleotides involved in the 29 
triple-helix formation are colored blue. Nucleotides involved in the formation of the base triple 30 
and quintuple are highlighted in gray and orange backgrounds, respectively. 31 
(D–G) Base triples (D and E) and base quintuples (F and G) in the triple helix. Hydrogen bonds 32 
between canonical and non-canonical base pairs are depicted with green and gray dashed lines, 33 
respectively. 34 
 20 
 1 
Figure 4 TracrRNA scaffold recognition 2 
(A) Binding of the tracrRNA scaffold to CjCas9 (stereo view). 3 
(B and C) Specific recognition of A63 (B) and A76/U80 (C). Hydrogen bonds are depicted by 4 
dashed lines. 5 
(D) Functional importance of the tracrRNA scaffold. The linearized plasmid target with the 5′-6 
AGAAACC-3′ PAM was incubated with CjCas9, together with either the full-length sgRNA 7 
(nucleotides 1–93), the sgRNA variants, or the SpCas9 sgRNA. 1–93, the full-length sgRNA; 8 
GGCG, the sgRNA variant, in which nucleotides 90–93 (CCGC) were replaced with GGCG; 1–9 
85, the sgRNA variant, in which nucleotides 86–93 were truncated; Sp, the SpCas9 sgRNA. 10 
 11 
Figure 5 PAM recognition 12 
(A) Binding of the PAM duplex to CjCas9. 13 
(B) Schematics of the PAM recognition by CjCas9. Hydrogen bonds are depicted by dashed 14 
lines. Water molecules are shown as red spheres. Water-mediated hydrogen bonds between the 15 
protein and the sugar-phosphate backbone are omitted for clarity. 16 
(C) Recognition of the 5′-AGAAACC-3′ PAM (stereo view). Water molecules are shown as red 17 
spheres. Hydrogen bonds are depicted by dashed lines. 18 
(D) Functional importance of the PAM-interacting residues. The linearized plasmid target with 19 
the 5′-AGAAACC-3′ PAM was incubated with either the wild type or the mutants of CjCas9, 20 
together with the sgRNA. 21 
See also Figure S3. 22 
 23 
Figure 6 Structural comparison of the Cas9 orthologs 24 
(A–D) Structures of CjCas9 (A), SpCas9 (PDB: 4UN3) (B), SaCas9 (PDB: 5CZZ) (C), and 25 
FnCas9 (PDB: 5B2O) (D) in complexes with their cognate sgRNAs and target DNAs. SpCas9 26 
and FnCas9 have structurally distinct subdomains inserted within their REC1 domains 27 
(previously referred to as the REC2 domains (Nishimasu et al., 2014; Hirano et al., 2016)). 28 
(E–H) Structures of the sgRNAs for CjCas9 (E), SpCas9 (PDB: 4OO8) (F), SaCas9 (PDB: 29 
5CZZ) (G), and FnCas9 (PDB: 5B2O) (H). The guide segments are omitted for clarity. 30 
See also Figures S4–S7. 31 
 32 
Figure 7 PAM recognition by the Cas9 orthologs 33 
 21 
(A–D) PAM recognition by CjCas9 (A), SpCas9 (PDB: 4UN3) (B), SaCas9 (PDB: 5CZZ) (C), 1 
and FnCas9 (PDB: 5B2O) (D). In (B), the subdomain inserted between β6 and β7 is omitted for 2 
clarity. The PAMs are highlighted in purple. The conserved core β-strands are numbered. Close-3 
up views for the PAM recognition are shown in right panels. 4 
  5 
 22 
Table	1.	Data	collection	and	refinement	statistics	
	
5ʹ-AGAAACC-3ʹ	PAM	
(Native)	
5ʹ-AGAAACA-3ʹ	PAM	
(Native)	
5ʹ-AGAAACA-3ʹ	PAM	
(SeMet)	
Data	collection	 	 	 	
Beamline	 SLS	PX1	 SPring-8	BL41XU	 SPring-8	BL41XU	
Wavelength	(Å)	 1.0000	 1.0000	 0.9791	
Space	group	 P212121	 P212121	 P212121	
Cell	dimensions	 	 	 	
a,	b,	c	(Å)	 104.3,	105.1,	136.5	 102.0,	103.9,	134.5	 102.0,	104.2,	134.6	
α,	β,	γ	(°)	 90,	90,	90	 90,	90,	90	 90,	90,	90	
Resolution	(Å)*	 136.5–2.4	(2.47–2.40)	 103.9–2.3	(2.36–2.30)	 49.5–2.2	(2.25–2.20)	
Rmerge	 0.150	(0.882)	 0.105	(0.783)	 0.075	(0.967)	
Rpim	 0.043	(0.529)	 0.032	(0.316)	 0.031	(0.396)	
I/σI	 13.8	(1.6)	 12.4	(2.4)	 14.2	(2.6)	
Completeness	(%)	 100	(100)	 99.8	(99.8)	 100	(100)	
Multiplicity	 12.9	(13.4)	 10.4	(7.0)	 6.8	(6.9)	
CC	(1/2)	 0.998	(0.757)	 0.986	(0.875)	 0.999	(0.866)	
	 	 	 	
Refinement	 	 	 	
Resolution	(Å)	 52.6–2.4	 72.8–2.3	 	
No.	reflections	 59,303	 63,923	 	
Rwork	/	Rfree	 0.190	/	0.221	 0.200	/	0.231	 	
No.	atoms	 	 	 	
				Protein	 5,929	 5,925	 	
				Nucleic	acid	 2,715	 2,715	 	
				Solvent	 323	 279	 	
B-factors	(Å2)	 	 	 	
				Protein	 59	 65	 	
				Nucleic	acid	 49	 54	 	
				Solvent	 40	 45	 	
R.m.s.	deviations	 	 	 	
				Bond	lengths	(Å)	 0.0023	 0.0024	 	
				Bond	angles	(°)	 0.498	 0.515	 	
Ramachandran	plot	(%)	 	 	 	
				Favored	region	 97.28	 96.58	 	
				Allowed	region	 2.58	 3.01	 	
				Outlier	region	 0.14	 0.41	 	
*Values	in	parentheses	are	for	the	highest	resolution	shell.	
 1 
Figure 1
Position
C
G
AG
A
A
T
CA
C
0.0
1.0
Bi
ts
2 3 4 5 6 71
A C
B
Substrate
Product
Product
4.0 -
3.0 -
2.0 -
1.5 -
1.0 -
(kb)
0.5 -
– A G C T
5′-AGANACC-3′
– ACA GCA CCA TCA AAA AGA ATA ACG ACC ACT
Substrate
Product
Product
5′-AGAANNN-3′
4.0 -
3.0 -
2.0 -
1.5 -
1.0 -
(kb)
0.5 -
CCTTTAATCCACGCGAACCG
||||||||||||||||||||
GGAAAUUAGGUGCGCUUGGCGUUUUAGUCCCUG
                    ||||||||||||
                    UAAAAUCAGGGAA
A
Guide (spacer)
Repeat
Antirepeat
Tetraloop
−1
Stem 1
Stem 2
Stem 3
56 878857
58
63
62 64 68
80
86 84 81
70 73 76
Triple helix
21 32
37
49
48
53 50
1 20
5′
93
3′
20 1
1* 8*
−8
TS
NTS5′
3′
5′
3′
A
A
U
PAM
AGAAACCG
||||||||
TCTTTGGC
  U U  AA
    |  ||
CGCCA  UG  AGAAA
|||||  |   ||||
GCGGG  C   UCUGCGGGG UUA
          |    |||| | C
           A   UCCCC AA
D
1 45 77 23
5
42
7
48
1
64
1
48
0
641
480
64
1
77
8
79
2
82
8
98
4
NUC lobe
CjCas9
R
uv
C
-I
R
uv
C
-II
R
uv
C
-II
I
BH R
EC
2
R
EC
1
H
N
H
W
ED PI
REC lobe PLL
CjCas9-∆HNH
R
uv
C
-I
R
uv
C
-II
R
uv
C
-II
I
BH R
EC
2
R
EC
1
W
ED PI
Triple helix
R
EC
 lo
be
N
U
C
 lo
be
(GGGSGG)
WED WED
RuvC RuvC
REC2 REC2REC1REC1
PI PI
180º
TS
NTS
5′
5′
3′
5′
3′
3′
5′
3′
PAM
Repeat Repeat
Antirepeat Antirepeat
4.0 -
3.0 -
2.0 -
1.5 -
1.0 -
(kb)
0.5 -
W
T
D
8A
H
55
9A
Circular
– W
T
D
8A
H
55
9A
Linearized
–
Nicked
Linear
Supercoiled
Products
∆H
N
H
∆H
N
H
BA
C
Figure 2
Stem
 1
St
em
 2
Stem
 3
G
C
G
G
G
C
U
C
U
G
C
G
G
G
G
U
U
A
A
U
C
C
C
C
A
A
A
U
U
A
A
U
C
G
C
C
A
U
G
A
G
A
A
A
-
-
-
-
-
-
-
-
-
-
-
-
C
49
53
55
93
57
56
60 91
87
88
63
62
58
64
70
76
84
86
80
5′
3′
Triple helix
Figure 3
49
66
67
68
69
80
63
60
58
53
62
86
89
56
65
87
88
55 54 64
57
90
59
61
85
84 8483
82
81
70 70
71
73
72
74
75
76
77 77
78 79
93
92
91
52
51
50
A63
U48
G70
A76
C84
U85
A86
G58
C93
5′
5′
3′
49
66
67
68
69
80
63
60
58
53
62
86
89
56
65
87
88
55 54 64
57
90
59
61
85
83
82
81
71
73
72
74
75
76
78 79
93
92
91
52
51
50
5′
3′
U65 A53
A86
G62 U56
A89
C59
U57
G61
G92
C90
C64
G54
U55
A88
A87
3′
C
B D
E
G
F
A
Figure 4
Asn74
His67
His70
Asn66
A63
A76
U80
Ile964
Glu975
Arg977
Arg832
Glu980
Phe854
Phe982
Asp981
3′
C93
A86
A76
U80
U85
A63
WED
RuvC
REC2
REC1
PI
PI
BH
C93
A86
A76
U80
U85
A63
WED
RuvC
REC2
REC1
PI
B C
D
A
Substrate
Product
Product
4.0 -
3.0 -
2.0 -
1.5 -
1.0 -
(kb)
0.5 -
Sp1–
93
A6
3U
A7
6U
U
80
A
1–
85
G
G
C
G
–
Figure 5
3′
5′
3′
5′
5′
5′
WED
PI
NTS
TS
NTS
TS
PAM
PAM PAM
4*
5*
A4*
A5*
3*
2*1* 6*
7*
8*
Thr913
Ser915
Arg8
66
Ser951
G(−6)
G(−7)
A4*
A5*
G(−6)
G(−7)
3′
5′
5′
Thr913
Ser915
Arg8
66
Ser951
NTS
TS
3′5′
5′3′
As
n8
27
Se
r8
01
Ty
r8
50
Ty
r8
02
Th
r9
13
Se
r9
15
(S
er
91
5)
Ly
s8
90
Ar
g7
80
(M
et
83
0)
Se
r9
51
Ly
s9
40
Th
r9
16
Ar
g8
66
Ly
s9
50
Ar
g7
93
A1
*
T(
−1
)
G
2*
C
(−
2)
A3
*
T(
−3
)
A4
*
T(
−4
)
A5
*
T(
−5
)
C
6*
G
(−
6)
C
7*
G
(−
7)
G
8*
C
(−
8)
A
C
D
B
Substrate
Product
Product
4.0 -
3.0 -
2.0 -
1.5 -
1.0 -
(kb)
0.5 -
– W
T
R
86
6A
S9
15
A
S9
51
A
T9
13
A
Figure 6
Triple helix
WED WED
RuvC
REC2
REC1
REC2
REC1
REC2
REC2
REC1
REC2
REC1
PI RuvCPI
TS
NTS
TS
NTS
TS
NTS
5′
3′
3′
3′
3′
Repeat
Antirepeat
SL1
SL2
SL1
SL1
SL2
SL3
Linker
Linker
Linker
WED WED
RuvC
REC2
REC1-Ins
REC1-Ins
REC1-Ins
REC1
PI
PI-Ins
RuvCPI
TS
NTS
5′
Repeat
Antirepeat
WED WED
RuvC
REC2
REC1
REC1
REC1
PI RuvCPI
5′
Repeat
Antirepeat
WED WED
RuvC
REC2
PI RuvCPI
5′
Repeat
Antirepeat
A
B
C
D
E
F
G
H
CjCas9
R:AR duplex
R:AR duplex
R:AR duplex
R:AR duplex
CjCas9 sgRNA
SpCas9 sgRNA
SaCas9 sgRNA
FnCas9 sgRNA
SpCas9
SaCas9
FnCas9
180º
Figure 7
CjCas9
5′-NNNVRYM-3′
SpCas9
5′-NGG-3′
SaCas9
5′-NNGRRT-3′
FnCas9
5′-NGG-3′
3′
3′
5′
5′
5 6 78
9
4
3 1
2
3′
3′
5′
5′5 6 789 4
3
1
2
3′
3′
5′
5′
5 6 78
9
4
3
1 2
3′
3′
5′
5′
5
6
7
4
3
1
2
5′
3′
5′
Ser915
Arg866
Ser951
A4*
A5*
G(−6)
G(−7)
5
6
7
5′
5′
Asn985
Asn986
Arg1015
Arg991
G3*
A4*
A5*
T6*
5
6
7
3′
5′
5′
Arg1335
Arg1333
G2*
G3*
5 6
7
5′
5′
Arg1585
Arg1556
G2*
G3*5
6
7
A
B
C
D
AA
C
C 
  6
%
A   
4%
T
A   6%
C   2%
AC   2%
GC   0.6%
G
C
A   8%
C   0.9%
T
A   3%
T
G
C   1%
C
A
T
C
   5%
A   2%
G
   1%
C
C
   4%
A   4%
A
5%
   C
G
1%
   C
G
C
4%
   A
3%   
C
T 1%   C
C C 1%   A
G
A
C
9%   A
6%   CT
6%
   A
A
4%
   C
G
1%
   C
G
C
3%
   C
0.6%
   T
0.7%
   T
5′ NNNNNNN 3′
4 5 6 7
Figure S1. CjCas9 PAM specificity
The results of the in vitro PAM discovery assay are represented as the PAM wheel (Leenay et al., 2016). 
The area of the sector indicates the relative enrichment in the library.
Related to Figure 1.
Figure S2. Schematic of the nucleic-acid recognition
Residues that interact with nucleic acids via their main chain are shown in parentheses. Water-mediated hydrogen bonds are omitted for clarity.
Related to Figure 2.
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Figure S3. PAM recognition
(A and B) Interactions between Thr913 and dA4* (A) and modeled dT4* (B).
(C) Superimposition of the 5′-AGAAACC-3′ PAM complex (semitransparent gray) and the 5′-AGAAACA-3′ PAM complex (colored) (stereo view).
(D) Recognition of the 5′-AGAAACA-3′ PAM (stereo view). Hydrogen bonds are depicted by dashed lines.
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Figure S4. RNA-guided DNA targeting
(A) Recognition of the sgRNA seed region by CjCas9 (stereo view). The target DNA strand is omitted for clarity.
(B) Recognition of the +1 phosphate by CjCas9 (stereo view).
(C) Functional importance of the phosphate lock loop. The linearized plasmid target with the 5′-AGAAACC-3′ PAM was incubated with either the 
wild type or the T791A mutant of CjCas9, together with the sgRNA.
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Figure S5. Recognition of the repeat-antirepeat duplex by the Cas9 orthologs
(A–D) Species-specific recognition of the repeat-antirepeat duplex by the REC1/WED domains of CjCas9 (A), SpCas9 (PDB: 4UN3) (B), SaCas9 (PDB: 5CZZ) 
(C), and FnCas9 (PDB: 5B2O) (D).
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Figure S6. Comparison of the DNA cleavage activities of CjCas9 and SpCas9
The linearized plasmid targets with the 5′-TGG-3′ PAM and the 5′-AGAAACC-3′ PAM were incubated at 37°C for 
5 min with SpCas9 (10–100 nM) and CjCas9 (10–100 nM) in the presence of their cognate sgRNAs, respectively.
Related to Figure 6.
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Figure S7. Structures of the RNA triple helices
(A–D) Structures of the CjCas9 tracrRNA (A), the telomerase RNA subunit TER (PDB: 1YMO) (B), the SAM-II riboswitch (PDB: 2QWY) (C), 
and the long noncoding RNA MALAT1 (PDB: 4PLX) (D) (stereo view). The U•A-U triples are depicted as stick models. S, stem; L, loop.
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Table S1 Oligonucleotides, related to the STAR Methods 
Oligonucleotides used to generate the CjCas9 expression vector (pE‐SUMO‐CjCas9, with the TEV recognition site between His6‐SUMO and CjCas9) 
PCR template  Forward primer  Reverse primer 
pE‐SUMO (modified)  ACTCGAGCACCACCACCACC  CATATGGGATCCTTGGAAGTACAAG 
pColdGST‐CjCas9  CAAGGATCCCATATGGCCCGCATCCTCGCTTTC  TGGTGGTGCTCGAGTTTATTTCTTAAAATCCTCGCGCTG 
Oligonucleotides used to introduce the CjCas9 mutations (pE‐SUMO‐CjCas9) 
Mutation  Forward primer  Reverse primer 
ΔHNH  TACATTGCGCGACTGGTTC  CCCCCCGGACCCCCCCCCCAATTCGATATTTATTTTGTGCAC 
D8A  GCGATCGGAATCTCTAGTATCGGATG  GAAAGCGAGGATGCGGGC 
H559A  GCGATCTATCCGTATAGCAGGTCATTTGAC  GTCGATCTCCAGCATTTTCTCGTC 
T791A  GAAGAGGCATTCCGCAAGGAAGAGG  GCGGAATGCCTCTTCGTGCAGTGC 
R866A  GTGGCTGCGTCGAAGAAAGGAGAGATC  TCTTCGACGCAGCCACCGCCTTATTTGG 
T913A  AGCAGTACAGTGTCCCTGATTGTGAGCAAGC  CGCGAAGGCGTTATAATAAACAAATTCTGGTTCC 
S915A  ACAGTGTCCCTGATTGTGAGCAAGC  CGCGCTCGTGAAGGCGTTATAATAAACAAATTCTG 
S951A  GCAAAGGCAATTGGCATCCAAAACCTG  GCCAATTGCCTTTGCGATGACCTCCTT 
DNA oligonucleotides used for crystallization 
PAM sequence  Target DNA strand  Non‐target DNA strand 
AGAAACA  CTGTTTCTGCCAAGCGCACCTAATTTCC  AGAAACAG 
AGAAACC  CGGTTTCTGCCAAGCGCACCTAATTTCC  AGAAACCG 
sgRNA 
Cj sgRNA 1‐93  GGAAATTAGGTGCGCTTGGCGTTTTAGTCCCTGAAAAGGGACTAAAATAAAGAGTTTGCGGGACTCTGCGGGGTTACAATCCCCTAAAACCGC 
Cj sgRNA A63U  GGAAATTAGGTGCGCTTGGCGTTTTAGTCCCTGAAAAGGGACTAAAATAAAGAGTTTGCGGGTCTCTGCGGGGTTACAATCCCCTAAAACCGC 
Cj sgRNA A76U  GGAAATTAGGTGCGCTTGGCGTTTTAGTCCCTGAAAAGGGACTAAAATAAAGAGTTTGCGGGACTCTGCGGGGTTTCAATCCCCTAAAACCGC 
Cj sgRNA U80A  GGAAATTAGGTGCGCTTGGCGTTTTAGTCCCTGAAAAGGGACTAAAATAAAGAGTTTGCGGGACTCTGCGGGGTTACAAACCCCTAAAACCGC 
Cj sgRNA GGCG  GGAAATTAGGTGCGCTTGGCGTTTTAGTCCCTGAAAAGGGACTAAAATAAAGAGTTTGCGGGACTCTGCGGGGTTACAATCCCCTAAAAGGCG 
Cj sgRNA 1‐85  GGAAATTAGGTGCGCTTGGCGTTTTAGTCCCTGAAAAGGGACTAAAATAAAGAGTTTGCGGGACTCTGCGGGGTTACAATCCCCT 
Sp sgRNA  GGAAAUUAGGUGCGCUUGGCGUUUUAGAGCUAGAAAUAGCAAGUUAAAAUAAGGCUAGUCCGUUAUCAACUUGAAAAAGUGGCACCGAGUCGGUGCUU
Oligonucleotides used to introduce the sgRNA mutations (pUC119‐sgRNA) 
Mutation  Forward primer  Reverse primer 
A63U  TCTCTGCGGGGTTACAATCCCCTAAAACCGC  CCCGCAAACTCTTTATTTTAGTCCCTTTTC 
A76U  TCAATCCCCTAAAACCGCTTGTACCGAGCTCG  AACCCCGCAGAGTCCCGCAAACTCTTTATTTTAG 
U80A  ACCCCTAAAACCGCTTGTACCGAGCTCGAATTCAC  TTGTAACCCCGCAGAGTCCCGCAAACTC 
GGCG  GGCGTTGTACCGAGCTCGAATTCACTGGCCGTCG  TTTTAGGGGATTGTAACCCCGCAGAGTCCCGC 
Oligonucleotides used to generate the dsDNA templates for in vitro transcription 
sgRNA  Forward primer  Reverse primer 
1‐93, A63U, A76U  AGCGCCCAATACGCAAAC  GCGGTTTTAGGGGATTG 
U80A  AGCGCCCAATACGCAAAC  GCGGTTTTAGGGGTTTG 
GGCG  AGCGCCCAATACGCAAAC  CGCCTTTTAGGGGATTG 
1‐85  AGCGCCCAATACGCAAAC  AGGGGATTGTAACCCCGCAGAGTCCC 
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DNA oligos (for crystallization) This paper Table S1 
CjCas9 sgRNA This paper Table S1 
CjCas9 sgRNA, various mutants This paper Table S1 
SpCas9 sgRNA Nishimasu et al., 2014 Table S1 
Software and Algorithms 
DIALS Waterman et al., 2013 http://dials.lbl.gov 
AIMLESS Evans and 
Murshudov, 2013 
http://www.ccp4.ac.u
k/html/aimless.html 
Buccaneer Cowtan, 2006 http://www.ysbl.york.
ac.uk/~cowtan/bucc
aneer/buccaneer.ht
ml 
	COOT Emsley and Cowtan, 
2004 
http://www2.mrc-
lmb.cam.ac.uk/perso
nal/pemsley/coot 
PHENIX Adams et al., 2010 https://www.phenix-
online.org 
CueMol N/A http://www.cuemol.or
g 
Krona Ondov et al., 2011 https://github.com/m
arbl/Krona/wiki 
WebLogo Crooks et al., 2004 http://weblogo.threep
lusone.com/ 
Other 
Amicon Ultra-4 Centrifugal Filter Units - 10,000 NMWL Millipore UFC801024 
Ni-NTA Superflow QIAGEN 30450 
HiTrap Heparin HP GE Healthcare 17040701 
HiLoad 16/600 Superdex 200 pg GE Healthcare 28989335 
Superdex 200 Increase 10/300 GL GE Healthcare 28990944 
Whatman Elutrap electroelution system Sigma-Aldrich WHA10447705 
 
